{"id":43716,"date":"2022-07-16T14:26:24","date_gmt":"2022-07-16T18:26:24","guid":{"rendered":"https:\/\/sciencebusiness.technewslit.com\/?p=43716"},"modified":"2022-07-18T11:40:01","modified_gmt":"2022-07-18T15:40:01","slug":"infographic-us-biotech-investments-stay-strong","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=43716","title":{"rendered":"Infographic – US Biotech Investments Stay Strong"},"content":{"rendered":"
\"Chart:<\/a>
Click on image for full-size view (Pitchbook, NVCA)<\/figcaption><\/figure>\n

16 July 2022. The first half half of 2022 shows venture investments in U.S. biotechnology start-ups cooled from the blistering pace of last year, but biotech remains a robust sector. Data on venture capital investments in the U.S. for the first six months of 2022 were reported this week<\/a> by National Venture Capital Association and investment market research company Pitchbook (registration required).<\/p>\n

The Pitchbook-NVCA Venture Monitor report shows in 2022 so far, biotech and pharmaceutical start-ups in the U.S. raised $17.8 billion in 512 venture deals. While the pace of investment dollars and deals does not quite match the white-hot rates experienced in 2021, this industry is still on track to meet or exceed the totals of $28.1 billion raised in 1,097 deals in 2020. In fact, the $17.8 billion raised in the first half of of 2022, already exceeds the $17.7 billion in total investment dollars raised for biotech and pharma start-ups during all of 2019.<\/p>\n

Another sign of strength in this industry group is the larger deal sizes this year. The average venture capital deal among biotech or pharma start-ups so far in 2022 exceeds $40 million, and the median size deal of $10.6 million, recorded by at least half of the transactions, is in both cases higher than the average and median deal sizes in the previous two years, and double that of 2019.<\/p>\n

Biotech and pharma companies raising funds in their third or fourth venture rounds continue to make up a larger percentage of investment deals. So far in 2022, nearly four in 10 venture deals (38%) are made in those C and D rounds, a growing trend in this sector since 2019. Almost as many deals (36%) are made with biotech and pharma companies in rounds A and B, but only about a quarter (26%) of the deals so far in 2022 are made with the newest start-ups, those raising funds in angel and seed rounds.<\/p>\n

More from Science & Enterprise:<\/p>\n